| Abstract: | A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity. |
|
Patent landscape, scope, and claims summary: |
Comprehensive analysis of US Patent 7,794,716 claims and US patent landscape
US Patent 7,794,716 is not analyzable on claims/patent-landscape grounds from the information provided. The only content supplied is “The claims are:” without the claim text, a claim list, or a dependent/independent-claim structure. Without the actual claims (verbatim or structured), no complete and accurate claim chart, infringement-risk mapping, or invalidity/obviousness/anticipation analysis can be produced.
Claims and coverage: what is required to analyze US 7,794,716
- Claim-by-claim construction depends on the exact wording of:
- independent claims (preamble terms, exerted limitations, functional language)
- dependent claims (added structural/functional limitations)
- definitions (terms like “comprising,” “effective amount,” “module,” “system,” “processor,” “therapeutic,” “substrate,” etc.)
- Landscape assessment depends on identifying:
- the claimed active/compound class (or biological target)
- the delivery system or formulation type
- the method-of-treatment or device functionality
- the jurisdiction-specific filings and continuations that likely share priority
Patent landscape: what cannot be completed without the claims
A proper “critical” landscape requires mapping the claim scope to:
- same-family continuations and divisionals (same priority chain)
- closest prior art patents and published applications (US and WO)
- prosecution history and claim amendments (for narrowing scope)
- related Orange Book, if any (brand drug/formulation connection)
- litigation or PTAB history involving the same patent family
Because none of those claim-identifying elements are available, producing a complete, accurate analysis would require inventing claim content, which is disallowed.
Key Takeaways
- A comprehensive analysis of US Patent 7,794,716 cannot be produced from the provided input because the claim text is missing.
- Claim-level language is a gating dependency for any valid coverage, validity, and landscape assessment.
FAQs
- How are patent landscapes typically mapped when claim text is missing?
They cannot be mapped reliably without claim language; mapping requires a defined claim scope.
- What drives the choice of relevant prior art for an issued US patent?
The patent’s specific technical limitations and claim structure.
- Why do dependent claims matter for infringement risk?
They add concrete limitations that change both infringement and invalidity analyses.
- How does prosecution history affect claim scope?
It can narrow or clarify terms; analyzing it requires knowing what was amended and why.
- What key datasets are used for a US patent landscape?
US application family data, citations, PAIR/Prosecution records, litigation/PTAB dockets, and (if applicable) Orange Book listings.
References (APA)
- (No sources cited because US 7,794,716 claim text and bibliographic context were not provided.)
More… ↓
⤷ Start Trial
|
